OncWeekly Content Page - Page 8

DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma

Golidocitinib Shows Promise for Treating Refractory/Relapsed Peripheral T-Cell Lymphoma: JACKPOT8 Study Analysis

Nov 20, 2023

CLL (Chronic Lymphocytic Leukemia),DLBCL (Diffuse Large B Cell Lymphoma),Leukemia,Lymphoma

Rapcabtagene Autoleucel Shows Durable Efficacy And Manageable Safety In R/R DLBCL Patients

Nov 08, 2023

DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma)

Pirtobrutinib Found Safe And Effective In cBTKi Pre‑Treated MCL

Nov 03, 2023

DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma

Tafasitamab Shows Five‑Year Efficacy And Safety In R/R DLBCL Patients

Nov 02, 2023

Advertisement

DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma

Epcoritamab + R-CHOP Found Effective & Safe in 1st-Line High-Risk DLBCL

Oct 23, 2023

DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma

Epcoritamab With Rituximab + R² Show Durable Responses In High-risk FL Patients

Oct 17, 2023

DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma)

Subcutaneous Epcoritamab Is Well-Tolerated And Effective In Patients With R/R LBCL

Oct 05, 2023

DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma)

Epcoritamab Shows Lasting Remissions in R/R LBCL Patients

Oct 04, 2023

Previous
1
…
6
7
8
9
10
11
Next

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Newsletter

Advertisement